Bevacizumab Erlotinib Switch Maintenance in Advanced Gallbladder & Cholangiocarcinoma Journal of Clinical Oncology doi.org/10.1200/JCO.23… 🔎BEER BTC Phase II, 98 pts 🇮🇳, 80% gallbladder 👉mPFS 3.1 vs 5.3 mo 👉Interesting concept, modest benefit...molecular correlates? ESMO - Eur. Oncology EASLnews ILCA

Trastuzumab Deruxtecan in HER2–Expressing BTC Journal of Clinical Oncology doi.org/10.1200/JCO.23… 🔎HERB phs II 🇰🇷, 32 pts 👉ORR 36%, mPFS 5.1 mo, mOS 7.1 mo 🧐disappointing OS for selected subgroup. IO- combinations? Front-line? ESMO - Eur. Oncology EASLnews ILCA

Devimistat (CPI-613) with mFFX vs FFX for Metastatic #PDAC Journal of Clinical Oncology doi.org/10.1200/JCO.23… 🔎Phase III AVENGER 500 👉mPFS 7.8 vs 8 mo, mOS 11.1 vs 11.73 mo 👉Devimistat: inhibitor of PDH and aKGDH 🧐Interesting MOA, unfortunately ⛔️, combo w/ FFX feasible ESMO - Eur. Oncology

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic #PDAC Journal of Clinical Oncology doi.org/10.1200/JCO.24… 🔎EXTEND Phs II, 40 pts, pts with ≤five mets 👉mPFS time 10.3 vs 2.5 mo, mOS 12 vs 10 mo 🧐Proof of concept, reassuring to invest "more".. ESMO - Eur. Oncology

Clinical implementation of simultaneous multiple biomarkers testing for metastatic gastroesophageal adenocarcinoma ESMO Gastrointestinal Oncology 🔎 🇯🇵RWD, 202 pts ❓What do to when Her2 & CLDN18.2 pos (4 pts)? 👉personalized treatment in GE cancer! 🧐Still 20 - 40% marker ⛔️

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer & Other Malignancies Targetable with MET Inhibitors Cancer Discovery doi.org/10.1158/2159-8… 👉very rare alteration in most solid tumors, 0.5% 🧐but very useful data ESMO - Eur. Oncology

🔥off the press Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable HCC Journal of Clinical Oncology doi.org/10.1200/JCO.23… 👉STRIDE & durvalumab associated with similar improvements for PROs ESMO - Eur. Oncology EASLnews ILCA #livertwitter

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer Journal of Clinical Oncology doi.org/10.1200/JCO.23… 🔎CALGB/SWOG 80702 (Alliance) 👉improved DFS & OS in tumors w/ PIK3CA mutations ❓ready of implementation in clinical practice ESMO - Eur. Oncology

Nivolumab with or without Ipilimumab Combined with SBRT in Biliary Tract Cancer Clinical Cancer Research doi.org/10.1158/1078-0… 🔎Phs 2 Study, 70% 2nd line 👉42 pts SBRT/nivolumab/ipilimumab: CPR 31%, ORR 12%, mPFS 1.7 mo, mOS 5.4 mo, 1 Gr 5 AE 🤨Not convincing, is there a role for SBRT in

Neratinib Alone or with Immune Checkpoint Inhibitors with or without mTORi in Fibrolamellar Carcinoma Liver Cancer doi.org/10.1159/000540… 👉15 pts, interesting study design, benefit for some 🤨Really difficult to treat cancer, we need to do better ESMO - Eur. Oncology EASL Education ILCA

Challenges of estimating treatment effects after a positive interim analysis Oncology Advance doi.org/10.1016/j.ejca… 👉IAs may overestimate the true magnitude of benefit in some cases and underestimate it in others 🧐Food for thoughts ESMO - Eur. Oncology EASL Education ILCA

Clinical Outcomes and Histologic Findings of pts With HCC With Durable Partial Response or Durable Stable Disease After Atezolizumab + Bevacizumab Journal of Clinical Oncology doi.org/10.1200/JCO.24… 🔎Imbrave150 & RWD 👉favorable PFS & OS + high rates of pCR in pts w/ PR for ≥6 mo ESMO - Eur. Oncology

Bispecific antibodies: advancing precision oncology Trends in Cancer doi.org/10.1016/j.trec… 👉Bispecific antibodies are on the rise with promising data 👏Excellent in depth review ESMO - Eur. Oncology

BRAF + EGFR +/- MEK inhibitors after ICI in BRAF V600E mutated & MSI CRC European Journal of Cancer doi.org/10.1016/j.ejca… 👉Lower ORR & DCR, but similar PFS & OS compared to pMMR/MSS BRAFm CRC 🧐Intersting question & reassuring data ESMO - Eur. Oncology

Distinct clinical outcomes & biological features of specific KRAS mutants in human pancreatic cancer Cancer Cell doi.org/10.1016/j.ccel… 👉KRASG12R enriched in early stage w/ reduced nodal disease + distant recurrence 👉improved OS 🧐 Supports KRAS mutational testing in #PDAC

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies & for steering drug development Annals of Oncology doi.org/10.1016/j.anno… 👏Excellent concept ESMO - Eur. Oncology

Trastuzumab deruxtecan in HER2+ advanced mCRC The Lancet Oncology doi.org/10.1016/S1470-… 🔎DESTINY-CRC02 phs 2, 122 pts 👉5·4 & 6·4 mg/kg 👉ORR 37·8% & 27·5% 👉mPFS 5·8 & 5·5 mo 👉mOS 13·4 mo & NE 🧐support approval for pts with HER2-positive solid tumours ESMO - Eur. Oncology

Alternating gemcitabine/nab-paclitaxel and gemcitabine vs continuous gemcitabine/nab-paclitaxel after induction Tx of #PDAC The Lancet Oncology doi.org/10.1016/S2468-… 🔎 ALPACA phs 2, 325 pts 👉Similar OS, but improved tolerability 🧐Alternating schedule may be considered ESMO - Eur. Oncology

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in mBRAF Cancers Using Pharmacokinetics-Informed Dose Escalation Cancer Discovery doi.org/10.1158/2159-8… 👏efficient dose escalation concept 👉compelling activity in resistent pts 🤩great to see the new generation